$-0.01 EPS Expected for Antibe Therapeutics Inc (ATE)

November 25, 2017 – By Hazel Jackson

Analysts await Antibe Therapeutics Inc (CVE:ATE) to report earnings on December, 5. They expect $-0.01 earnings per share, 0.00 % or $0.00 from last year’s $-0.01 per share. After $-0.02 actual earnings per share reported by Antibe Therapeutics Inc for the previous quarter, Wall Street now forecasts -50.00 % EPS growth. The stock increased 5.56% or $0.005 on November 24, reaching $0.095. About 246,825 shares traded or 102.62% up from the average. Antibe Therapeutics Inc (CVE:ATE) has 0.00% since November 25, 2016 and is . It has underperformed by 16.70% the S&P500.

Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The company has market cap of $15.48 million. The Firm is focused on pain, inflammation and regenerative medicine. It currently has negative earnings. The Company’s divisions include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places.

More notable recent Antibe Therapeutics Inc (CVE:ATE) news were published by: Businesswire.com which released: “Antibe Therapeutics Engages MKR Group for US Investor Relations” on February 20, 2017, also Businesswire.com with their article: “Antibe Therapeutics Announces Successful Phase 2 Trial of ATB-346 in …” published on August 08, 2016, Businesswire.com published: “Antibe Therapeutics Announces Strategic Transactions” on October 06, 2015. More interesting news about Antibe Therapeutics Inc (CVE:ATE) were released by: Businesswire.com and their article: “Antibe Therapeutics Announces Appointment of the Giordano Group, Inc, a …” published on March 31, 2016 as well as Businesswire.com‘s news article titled: “Antibe Therapeutics Reports Q1 2018 Interim Financial and Operating Results” with publication date: August 29, 2017.